Disclaimer

The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR® therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe.

Annual Report 2020 Download

Share Price

SEQUANA MEDICAL

ISIN: XXXXXXXXXXXXX-XXXX Updated at 11:05:33

EURO 22.40

XXXXX.XX

+2.18%

For more information, please consult Euronext

Prev close
21.84

Open
20.60

Volume
17578

Lowest price
10.10

Highest price
20.20

Bid price
20.60

Ask price
20.60

Trading sessions
200

Capitalization
246.01M

Share Data

Status as of 30 April 2021

  • Outstanding share capital: EUR 1,924,846.39
  • Outstanding voting securities: 18,576,252 shares
  • Outstanding voting rights (“denominator”): 18,576,252 voting rights
  • Voting securities that can still be issued: 1,747,127 shares (each share entailing one voting right)
Major Shareholdings

Last update: 25 March 2021

Overview of major shareholdings

This graph represents Sequana Medical’s major shareholders, based on transparency notifications received by the Company, to date.

Overview of transparency notifications received to date

The Belgian Transparency Act refers to article 14 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings in issuers shares of which are admitted to trading on a regulated market and laying down miscellaneous provision.
Pursuant to this Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA) is required by all natural and legal persons in each case where the percentage of voting rights attached to the securities held by such persons in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

For more information and the appropriate transparency forms, please contact Sequana Medical Investor Relations (ir@sequanamedical.com) or the FSMA.

Shareholder Date of notification Transparency notification Press release
Venture Incubator AG / VI Partners AG 19-Feb-2021 Download pdf 23-Feb-2021
LSP Health Economics Fund Management B.V. 19-Feb-2021 Download pdf 23-Feb-2021
NeoMed IV Extension L.P. / NeoMed Innovation V L.P. 19-Feb-2021 Download pdf 23-Feb-2021
Federale Participatie- en Investeringsmaatschappij NV / Belfius Insurance SA 18-Feb-2020 Download pdf 21-Feb-2020
Capricorn Heath-tech Fund NV / Quest for Growth NV 14-Feb-2020 Download pdf 21-Feb-2020
GRAC Société Simple 30-Jan-2020 Download pdf 03-Feb-2020
NeoMed IV Extension L.P. / NeoMed Innovation V L.P. 30-Jan-2020 Download pdf 03-Feb-2020
Newton Biocapital I Pricav Privée SA 21-Feb-2019 Download pdf 25-Feb-2019
Venture Incubator AG / VI Partners AG 21-Feb-2019 Download pdf 25-Feb-2019
NeoMed IV Extension L.P. / NeoMed Innovation V L.P. 20-Feb-2019 Download pdf 25-Feb-2019
LSP Health Economics Fund Management B.V. 19-Feb-2019 Download pdf 25-Feb-2019
Federale Participatie- en Investeringsmaatschappij N.V. 18-Feb-2019 Download pdf 25-Feb-2019
Participatiemaatschappij Vlaanderen NV 18-Feb-2019 Download pdf 25-Feb-2019
Capricorn Health-tech Fund NV / Quest for Growth NV 18-Feb-2019 Download pdf 25-Feb-2019
Shareholder Meetings

May 27, 2021

Annual and Extraordinary General Meetings

Convening Notice

Attendance Form NL/EN

Proxy Form NL/EN

Vote by Letter Form NL/EN

Outstanding Shares and Voting Rights NL/EN

Annual report 2020

Statutory annual accounts for the year ended 31 December 2020

Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2020

Statutory auditor’s report on the annual accounts for the year ended 31 December 2020

Statutory auditor’s report on the 2021 Share Options (full version in Dutch only)

Report of the Board of Directors on the annual accounts for the year ended 31 December 2020

Report of the Board of Directors on the renewal of the authorised capital

Report of the Board of Directors on the 2021 Share Options


May 28, 2020

Annual and Extraordinary General Meetings

Minutes AGM

Minutes EGM

Convening Notice

Explanatory Note

Proxy Form NL/EN

Vote by Letter Form NL/EN

Outstanding Shares and Voting Rights

Annual report 2019

Statutory annual accounts for the year ended 31 December 2019

Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2019

Statutory auditor’s report on the annual accounts for the year ended 31 December 2019


May 23, 2019

Annual General Meeting

Minutes

Invitation

Explanatory Note

Proxy Form NL/EN

Vote by Mail Form EN / Vote by Mail Form NL (please complete the Dutch form)

Outstanding Shares and Voting Rights

Attendance Form EN / Attendance Form NL (please complete the Dutch form)

Annual report 2018

Statutory annual accounts for the year ended 31 December 2018

Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2018

Statutory auditor’s report on the annual accounts for the year ended 31 December 2018


April 25, 2019

Extraordinary General Meeting

Minutes NL

Invitation

Explanatory Note

Proxy Form EN / Proxy Form NL (please complete the Dutch form)

Vote by Mail Form EN / Vote by Mail Form NL (please complete the Dutch form)

Outstanding Shares and Voting Rights

Attendance Form EN / Attendance Form NL (please complete the Dutch form)

Other Regulated Information

March 25, 2021

Article 7:198 juncto articles 7:179 and 7:197 of the Belgian companies and Associations Code

Report of the Board of Directors – Dutch only

Report of the Statutory Auditor – Dutch only


February 9, 2021

Article 7:198 juncto articles 7:179 and 7:191 of the Belgian companies and Associations Code

Report of the Board of Directors

Report of the Statutory Auditor – full version in Dutch only


January 27, 2020

Article 7:198 juncto articles 7:179 and 7:191 of the Belgian companies and Associations Code

Report of the Board of Directors

Report of the Statutory Auditor on the proposal of a capital increase (within the framework of the authorized capital) with cancellation of the preferential subscription right – full version in Dutch only

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our. Privacy & Cookie Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close